

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFR α and kit

Xianming Deng^{a,b}, Wenjun Zhou^{a,b}, Ellen Weisberg^c, Jinhua Wang^{a,b}, Jianming Zhang^{a,b}, Takaaki Sasaki^d, Erik Nelson^c, James D. Griffin^c, Pasi A. Jänne^d, Nathanael S. Gray^{a,b,*}

^a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

^b Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 250 Longwood Ave., SGM 628, Boston, MA 02115, USA

^c Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA

^d Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

ARTICLE INFO

Article history:

Received 20 April 2012

Revised 28 May 2012

Accepted 29 May 2012

Available online 6 June 2012

Keywords:

Amino-indazole

Type-II kinase inhibitor

ABSTRACT

Here we describe the synthesis and characterization of a number of 3-amino-1H-indazol-6-yl-benzamides that were designed to target the 'DFG-out' conformation of the kinase activation loop. Several compounds such as **4** and **11** exhibit single-digit nanomolar EC₅₀s against FLT3, c-Kit and the gatekeeper T674M mutant of PDGFR α .

© 2012 Elsevier Ltd. All rights reserved.

Small molecule inhibitors of kinases such as Bcr-Abl, PDGFR, c-Kit, ALK, and EGFR have exhibited dramatic clinical efficacy in a range of tumors and have provided the impetus for a large effort to develop a new generation of kinase inhibitors.¹ In most cases, resistance emerges with the most common mechanism being selection for mutant kinases that are no longer effectively inhibited by the drugs. The most frequently observed mutation is the so-called 'gatekeeper' residue typically involving a conversion of a threonine in the wild-type kinase to an isoleucine or methionine in the mutant kinase.² One approach to overcoming this problem is to develop new inhibitors that exploit different binding sites or binding modes that avoid contacts with the gatekeeper amino acid. For example, a number of inhibitors that can overcome the T315I Bcr-Abl mutation, including GNF-7³, AP24534⁴, PHA-739358⁵, TG101113⁶ and HG-7-85-01⁷, have been reported.

Here we employed structure-based drug design to develop inhibitors that could target the 'DFG-out' conformation of the activation loop and that could overcome the T315I Bcr-Abl mutation.⁸ The starting point for our efforts was HG-7-85-01, a small molecule type II inhibitor that inhibits the proliferation of cells expressing the major imatinib-resistant gatekeeper mutants of BCR-ABL-T315I, Kit-T670I, PDGFR α -T674M/I, as well as Src-T341M/I.⁷ A co-crystal structure of HG-7-85-1 with c-Src (PDB ID: 4agw) revealed that the general binding mode of HG-7-85-01 to Src is sim-

ilar to that of imatinib, nilotinib and the DSA series of Src and Abl inhibitors.^{9,10} HG-7-85-01 binds to Src in the 'DFG-out' inactive conformation and makes five hydrogen bonds with the ATP-binding cleft.⁷ Using information gleaned from these examples,^{7,9,10} we designed the potential kinase inhibitor chemo-type, 3-amino-1H-indazol-6-yl-benzamide, by replacing the hinge-interacting 2-




Figure 1. Scaffold design strategy.

* Corresponding author.


E-mail address: nathanael_gray@dfci.harvard.edu (N.S. Gray).

amino-thiazolo-pyridine with 3-amino-indazole (Fig. 1).⁸ Amino-indazole hinge binders have been reported in a number of other kinase inhibitors including compounds targeting PDK1¹¹, ALK¹² and VEGFR2.¹³ Here we report the discovery and characterization of type II amino-indazole inhibitors with spectrum selective inhibition of FLT3, PDGFR α and c-Kit.

The amino-indazole scaffold is exemplified by structures I and II (Tables 1 and 2). Concise synthetic routes were developed to pre-

pare I and II (Schemes 1 and 2). Scheme 1 shows the details for the synthesis of compound 4, starting with condensation of 4-bromo-2-fluorobenzonitrile with hydrazine to afford 3-aminoindazole intermediate 1. The key intermediate, ethyl 3-(3-(cyclopropanecarboxamido)-1H-indazol-6-yl)benzoate 3, was obtained by acylation of 3-aminoindazole 1 with cyclopropanecarbonyl chloride followed by Suzuki coupling with 3-ethoxycarbonylphenylboronic acid. The final product 4 was obtained after ester hydrolysis and


Table 1
SAR of 3-(3-(cyclopropanecarboxamido)-1H-indazol-6-yl)benzamide (I)



Comps	Structure	Cellular antiproliferative activity ^a (EC ₅₀ , μ M)			
		MOLM13 (FLT3)	PDGFR α -T674 M-Ba/F ₃	Kit-T6071-Ba/F ₃	wt-Ba/F ₃
4		0.005	0.017	0.198	>10
5		0.325	1.315	0.637	3.3
6		1.713	0.232	1.519	3.6
7		>10	>10	>10	>10
8		>10	>10	>10	>10
9		3.752	0.256	>10	2.0

^a Cellular antiproliferative activity (EC₅₀, μ M) on MOLM13, mutant PDGFR α -T674M-Ba/F₃, mutant Kit-T6701-Ba/F₃ and wt-Ba/F₃, values are means of two experiments.

Table 2
SAR of 3-amino-1*H*-indazol-benzamides (II)



Comps	Structure	Cellular antiproliferative activity ^a (EC ₅₀ , μM)			
		MOLM13 (FLT3)	PDGFR α -T674M-Ba/F ₃	Kit-T6071-Ba/F ₃	wt-Ba/F ₃
4		0.005	0.017	0.198	>10
10		0.005	0.031	1.424	>10
11		0.002	0.001	0.177	3.1
12		0.559	0.078	2.908	>10
13		3.426	1.817	1.22	>10
14		0.035	0.927	1.094	2.0
15		<0.001	0.13	— ^b	0.12
16		0.033	0.845	5.366	5.3


(continued on next page)

Table 2 (continued)

Comps	Structure	Cellular antiproliferative activity ^a (EC ₅₀ , μM)			
		MOLM13 (FLT3)	PDGFRα-T674M-Ba/F3	Kit-T670I-Ba/F3	wt-Ba/F3
17		0.004	0.017	3.169	>10
18		<0.001	0.001	1.528	>10
22		0.002	0.001	0.727	4.4

^a Cellular antiproliferative activity (EC₅₀, μM) on MOLM13, mutant PDGFRα-T674M-Ba/F3, mutant Kit-T670I-Ba/F3 and wt-Ba/F3, values are means of two experiments.

^b Nonsensical value.



Scheme 1. Synthetic route of **4**. Reagents and conditions: (a) NH₂NH₂, *n*-BuOH, 130 °C, overnight, 98%; (b) cyclopropanecarbonyl chloride, pyridine, 0 °C, 77%; (c) (3-(ethoxycarbonyl)phenyl)boronic acid, Pd(dppf)Cl₂, Na₂CO₃ (1 N, aq), dioxane, 100 °C, 80%; (d) LiOH, THF/MeOH/H₂O; (e) 4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline, HATU, DIEA, DMSO, 45%.


amide bond formation. Compounds **5–9** were synthesized analogously using different amines in the final amide formation step and compounds **10–13** were also obtained following this synthetic route using different boronic acids.

Synthesis of **22** was accomplished by introduction of a boronic ester group to 6-bromo-*N*-methyl-1*H*-indazole-3-amine **20** followed by coupling with *N*-4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl-3-iodobenzamide (Scheme 2). Compounds **14–18** were obtained following this synthetic route.

To explore the selectivity profile of this amino-indazole scaffold as kinase inhibitors, representative compound **4** was screened against a diverse panel of 402 kinases (Ambit KINOMEScan) using an in vitro ATP-site competition binding assay at a concentration of 10 μM.¹⁴ The kinome-wide profiling revealed that this compound possessed a broad selectivity profile. The kinase exhibiting ambit scores less than 0.1% of the DMSO control for **4** are highlighted in a spot tree (Fig. 2, please see Supplementary data for full profiling results).^{14,15} Many of the kinases that were potentially bound by **4**, such as ABL, FLT3, KIT, p38 and PDGFR, are well known to show a predilection to being targeted by type II compounds that recognize the 'DFG-out' conformation.⁸

To corroborate a subset of the potential targets using cellular assays, we evaluated **4** in cell proliferation assays that are known to be dependent upon wild-type and mutant forms of Bcr-Abl, FLT3, PDGFRα and c-KIT kinase activity. These included MOLM13 (FLT3), Bcr-Abl- and Bcr-Abl-T315I-, PDGFRα-T674M-, and Kit-T670I transformed Ba/F3 cells. Wild-type Ba/F3 cells proliferate only in the presence of interleukin-3 (IL-3) while Ba/F3 cells transformed with oncogenic kinases such as Bcr-Abl become capable of growing in the absence of IL-3. This provides a robust and commonly used assay for selective kinase inhibition.¹⁶

The first synthesized compound **4** exhibited EC₅₀s of 5 nM, 17 nM, and 198 nM on MOLM13(FLT3), PDGFRα-T674M-Ba/F3 and Kit-T670I-Ba/F3 cells, respectively. Compound **4** did not inhibit growth of Kit-V559D-Ba/F3 and Kit-insAY-Ba/F3 at concentration of 1 μM. Surprisingly, **4** was only a single digit micromolar inhibitor of T315I-Bcr-Abl Ba/F3 cells. The EC₅₀ against parental Ba/F3 cells was higher than 10 μM, demonstrating that the antiproliferative activity was derived from on-target inhibition of the respective kinase. Encouraged by the potent activity against FLT3 and PDGFR, we next prepared a small set of compounds to investigate the structure–activity relationship (SAR) and validate our design



Scheme 2. Synthetic route of **22**. (a) phenyl chloroformate, pyridine, 0 °C, 40%; (b) LiAlH₄, dioxane, reflux, 53%; (c) pinacol diboron ester, Pd(dppf)Cl₂, dppf, KOAc, DMF, 100 °C, 90%; (d) *N*-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-iodobenzamide, Pd(dppf)Cl₂·Na₂CO₃ (1 N, aq), dioxane, 100 °C, 15%




Figure 2. KINOMEScan profiling of **4**. The compound was screened at a concentration of 10 μM against 402 kinases and the most potently bound kinases (score ≤0.1) are indicated by red circles. The kinase dendrogram was adapted and reproduced with permission from Cell signaling Technology, Inc.

strategy (Table 1). Replacement of substituted aniline in the ‘tail’ region (**5** and **6**) resulted in a dramatic loss of activity against all three targets. This indicated that *N*-ethylpiperazine moiety might have a key interaction with the target kinase in this region (see the discussion of modeling study). The simple alkyl amide analogs containing linear alkyl amine, cyclic amine and methyl amine (**7–9**) lost activity completely, except compound **9** which exhibited an EC₅₀ of 256 nM on PDGFRα-T674M. Collectively these results are consistent with this inhibitor functioning as a type-II kinase inhibitor of targets of FLT3, PDGFRα and c-KIT.

We next investigated the effects of using 6-methyl 1,3-substituted benzene, 2,5-substituted thiophene, and 2,5-substituted furan as linker motifs (Table 2 and 10–16). Comparing compounds **4** and **10**, the orientation of the amide (as found in nilotinib) is favored over the reverse amide orientation (as found in imatinib), respectively. Compound **10** maintained similar potency against FLT3 and PDGFRα-T674M, but exhibited sixfold decreased activity on Kit-T670I relative to compound **4**. Introduction of a flag-methyl on the benzene ring of linker region (**11**) resulted in a compound that exhibited similar activity against all three targets. Again we observed that *N*-ethylpiperazine moiety in the tail region was




Figure 3. Modeling study of **4**. (a) Binding mode comparison of **4** with HG-7-85-01 in the co-crystal structure of c-Src (PDB ID: 4agw). (b) Binding mode comparison of **4** with AP24534 in the co-crystal structure of Bcr-Abl-T315I (PDB ID: 3ik3). **4** (green carbon atom), HG-7-85-01 (cyan carbon atom), AP24534 (yellow carbon atom, the structure was included in Supplementary data) and hydrogen bonds indicated by hatched lines.

important to maintain potent inhibition (**11** vs **12** and **13**). Thiophene and furan linker analogs (**14–16**) exhibited good activity on FLT3, but lost potency against PDGFRα-T674M and Kit-T670I. Compound **15** exhibited significant general cytotoxicity with an

EC₅₀ of 120 nM on parental Ba/F3 cells suggesting that this compound engaged additional targets. We next investigated modifications to the 3-amino group of the 1*H*-indazole, which is predicted to interact with the hinge region of the kinase. Acetyl, free amino and methyl analogs (**17**, **18** and **22**) exhibited EC₅₀s of single-digit nanomolar potency against FLT3 and PDGFR α -T674M, but lost activity on Kit-T670I.

To better understand the structure and activity relationship of this amino-indazole scaffold, we performed a modeling study by comparing the binding mode of compound **4** with HG-7-85-01 in the co-crystal structure of c-Src (PDB ID: 4agw)⁷ and with AP24534 in a co-crystal structure with T315I Abl (PDB ID: 3ik3)⁴ (Fig. 3).¹⁷ Superimposing the bound conformation of **4** and HG-7-85-01, **4** is predicted to bind to Src in the 'DFG-out' inactive conformation and form four hydrogen bonding interactions (Fig. 3a). One hydrogen bond is predicted between the hinge region backbone carbonyl of E339 and the indazole NH. A pair of hydrogen bonds are predicted between the benzamide carbonyl and the backbone NH of D404 of the 'DFG-motif' and the benzamide NH and side chain carboxylate of E310 from the α C-helix. Finally, a hydrogen bond is predicted between the presumably protonated distal piperazine nitrogen and the backbone carbonyls of V383 and H384. This modeling can be used to rationalize some of the observed structure–activity relationships. For example, comparison of compounds with and without the piperazine ring (**4** vs **6**, **11** vs **13**) demonstrates that this functionality greatly improves potency against FLT3, PDGFR α -T674M and Kit-T670I. Similarly, the comparison of binding mode of **4** with that of AP24534 to T315I-Abl revealed the repulsive interaction between 'gatekeeper' I315 and **4** (Fig. 3b), which provides a possible explanation for the modest single digit micromolar activity of **4** against T315I Bcr-Abl Ba/F3 cells.

In summary, we have designed a new type II kinase inhibitor scaffold, 3-amino-1*H*-indazol-6-yl-benzamide, using structure-based design and scaffold morphing approaches. The combined use of kinome-wide kinase selectivity profiling followed by kinase-activity dependent cellular proliferation assays enabled the efficient development of highly potent inhibitors of FLT3 and PDGFR α -T674M. Despite having a broad kinase selectivity profile, compounds such as **4** and **22** are not general cytotoxic agents and exhibit more than 1000-fold selectivity for FLT3 and Kit-T670I dependent cellular growth. Further medicinal chemistry efforts are in progress to develop analogs from this compound series whose multitargeted inhibition profile is tailored for optimal activity against particular cancer genotypes.

Acknowledgments

This work was supported by the NIH Grant number CA130876-02. We thank Ambit Biosciences for technical support in the compound KINOMEScan profiling and Maria Nicolais for helping with Cell-Titer Glo experiments. The kinase dendrogram was adapted

and reproduced with permission from Cell Signaling Technology, Inc. (<http://www.cellsignal.com>).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2012.05.107>. These data include MOL files and InChIKeys of the most important compounds described in this article.

References and notes

- Zhang, J.; Yang, P. L.; Gray, N. S. *Nat. Rev. Cancer* **2009**, *9*, 28.
- Barouch-Bentov, R.; Sauer, K. *Expert Opin. Invest. Drugs* **2011**, *20*, 153.
- Choi, H. G.; Ren, P.; Adrian, F.; Sun, F.; Lee, H. S.; Wang, X.; Ding, Q.; Zhang, G.; Xie, Y.; Zhang, J.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W.; Mestan, J.; Gray, N. S.; Sim, T. *J. Med. Chem.* **2010**, *53*, 5439.
- O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W. S.; Xu, Q.; Metcalf, C. A., 3rd; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W.; Druker, B. J.; Clackson, T. *Cancer cell* **2009**, *16*, 401.
- Carpinelli, P.; Ceruti, R.; Giorgini, M. L.; Cappella, P.; Gianellini, L.; Croci, V.; Degrassi, A.; Texido, G.; Rocchetti, M.; Vianello, P.; Rusconi, L.; Storic, P.; Zugini, P.; Arrigoni, C.; Soncini, C.; Allii, C.; Patton, V.; Marsiglio, A.; Ballinari, D.; Pesenti, E.; Fancelli, D.; Moll, J. *Mol. Cancer Ther.* **2007**, *6*, 3158.
- Noronha, G.; Cao, J.; Chow, C. P.; Dneprovskaja, E.; Fine, R. M.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. *Curr. Top. Med. Chem.* **2008**, *8*, 905.
- Weisberg, E.; Choi, H. G.; Ray, A.; Barrett, R.; Zhang, J.; Sim, T.; Zhou, W.; Seeliger, M.; Cameron, M.; Azam, M.; Fletcher, J. A.; Debiec-Rychter, M.; Mayeda, M.; Moreno, D.; Kung, A. L.; Janne, P. A.; Khosravi-Far, R.; Melo, J. V.; Manley, P. W.; Adamia, S.; Wu, C.; Gray, N.; Griffin, J. D. *Blood* **2010**, *115*, 4206.
- Liu, Y.; Gray, N. S. *Nat. Chem. Biol.* **2006**, *2*, 358.
- Seeliger, M. A.; Ranjitkar, P.; Kasap, C.; Shan, Y.; Shaw, D. E.; Shah, N. P.; Kuriyan, J.; Maly, D. J. *Cancer Res.* **2009**, *69*, 2384.
- Seeliger, M. A.; Nagar, B.; Frank, F.; Cao, X.; Henderson, M. N.; Kuriyan, J. *Structure* **2007**, *15*, 299.
- Medina, J. R.; Becker, C. J.; Blackledge, C. W.; Duquenne, C.; Feng, Y.; Grant, S. W.; Heering, D.; Li, W. H.; Miller, W. H.; Romeril, S. P.; Scherzer, D.; Shu, A.; Bobko, M. A.; Chadderton, A. R.; Dumble, M.; Gardiner, C. M.; Gilbert, S.; Liu, Q.; Rabindran, S. K.; Sudakin, V.; Xiang, H.; Brady, P. G.; Campobasso, N.; Ward, P.; Axten, J. M. *J. Med. Chem.* **1871**, *2011*, 54.
- Menichincheri, M.; Bertrand, J. A.; Marchionni, C.; Nesi, M.; Orsini, P.; Panzeri, A.; PCT Int. Appl. WO2010069966A1.
- Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Harris, C. M.; Hickman, D.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Martin, R. L.; Olson, A. M.; Osterling, D. J.; Pease, L. J.; Soni, N. B.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Reuter, D. R.; Davidsen, S. K.; Michaelides, M. R. *J. Med. Chem.* **2007**, *50*, 1584.
- Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. L.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. *Nat. Biotechnol.* **2008**, *26*, 127.
- The image was generated by using the web-based TREEspotTM software (Ambit Biosciences, now part of DiscoverRx Corp.).
- Melnick, J. S.; Janes, J.; Kim, S.; Chang, J. Y.; Sipes, D. G.; Gunderson, D.; James, L.; Matzen, J. T.; Garcia, M. E.; Hood, T. L.; Beigi, R.; Xia, G.; Harig, R. A.; Asatryan, H.; Yan, S. F.; Zhou, Y.; Gu, X. J.; Saadat, A.; Zhou, V.; King, F. J.; Shaw, C. M.; Su, A. I.; Downs, R.; Gray, N. S.; Schultz, P. G.; Warmuth, M.; Caldwell, J. S. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 3153.
- Glide version 3.5 program was used for the docking study.